SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of Celgene Corporation

305

Celgene

CELG

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multimple myeloma, inflammatory diseases, and various forms of cancer.

CEO

Mark J. Alles

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

Summit, NJ

Years on Fortune 500 List

5

Employees

6,971

Key Financials (last fiscal year)
$ millions% change
Revenues ($M)$9,25620.7%
Profits ($M)$1,602-19.9%
Assets ($M)$27,053
Total Stockholder Equity ($M)$5,919
Market Value — as of March 31, 2016 ($M)$78,237
Profit Ratios
Profit as % of Revenues17.3%
Profits as % of Assets5.9%
Profits as % of Stockholder Equity27.1%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)1.94
EPS % Change (from 2014)-18.8%
EPS % Change (5 year annual rate)15.6%
EPS % Change (10 year annual rate)35.9%
Total Return
Total Return to Investors (2015)7.1%
Total Return to Investors (5 year, annualized)32.3%
Total Return to Investors (10 year, annualized)22.1%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a